© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Kitasamycin emerged in the post-war era, a period stacked with breakthroughs in antibiotic discovery. Japanese researchers discovered the compound in Streptomyces kitasatoensis after years of work with soil-dwelling microbes. The urgency of the era—facing bacterial infections that could sweep through hospitals—gave scientists the push to screen hundreds of actinomycetes for activity. Kitasamycin found its niche quickly in Asia and Europe thanks to its impressive performance against Gram-positive bacteria. At a time when penicillins hit resistance barriers, Kitasamycin gave doctors another tool, especially across respiratory infections and livestock disease control.
Kitasamycin falls squarely within the macrolide class, a group prized for tackling respiratory and soft tissue infections. It sports a 16-membered lactone ring, distinguishing itself from popular cousins like erythromycin, which rides with 14. In practice, product offerings take the form of phosphate or tartrate salts, allowing use in both medical and veterinary settings. Injectable and oral forms both fill out the catalog. In animal health, feed premixes and water-soluble powders help manage bacterial outbreaks that threaten livestock productivity and welfare.
Kitasamycin comes as a white or faintly yellow powder, lacking strong odor. It’s only slightly soluble in water, but dissolves well in many organic solvents—something that pushed forward different formulations over time. The molecular formula, C35H59NO13, and its structure drive its ability to wedge into bacterial ribosomes and block protein manufacture. High melting points and reasonable shelf stability turned kitasamycin into a practical pick for bulk storage and world-spanning trade. In the plant, samples respond well to pH adjustments, allowing for transformations into salts suited for oral administration.
Manufacturers stamp product lots with clear specifications: potency (usually measured in micrograms of base per milligram), loss on drying, residue on ignition, and microbiological purity all get tracked. Most producers follow pharmacopeial monographs—the Japanese and European Pharmacopeia lay out detailed requirements. Labels carry essential information: concentration, batch numbers, manufacture and expiration dates, storage cautions, along with intended uses. In veterinary applications, withdrawal period guidelines get printed up front, since food safety depends on strict residue limits in eggs, milk, and meat.
Industrial production of kitasamycin starts with carefully selected Streptomyces strains grown in bioreactors. Deep-tank fermentation provides nutrients—carbon sources like corn steep liquor, nitrogen from soy—while oxygenation needs constant monitoring. After several days, the broth ferments out; extraction with organic solvents pulls kitasamycin from the soup. Purification follows, often crystallization or chromatographic separation, looking for peak purity without blowing costs. After drying and milling, product passes through quality control before packaging. The structure barely shifts across standard manufacturing, but advanced factories sometimes tweak side chains to turn out derivatives.
For decades, chemists probed the macrolide core for new ways to outsmart resistant bacteria. Kitasamycin’s side chains at the sixth and twelfth carbon positions serve as hotspots for modification. Simple acylation or glycosylation steps can turn the parent compound into versions with longer half-lives or broader spectra. Laboratories synthesize hydrochloride, tartrate, and phosphate salts to help dissolve the compound in water or oil. When managing tricky animal infections, these adjustments matter—a tweak in the molecule can sometimes mean the difference between a drug that’s dosed once a day or three times.
Trade names pop up depending on the distributor and the market: Kitasaron, Kitasamycin Tartrate, Tarvid, and Mikamin-P, just to name a handful. Catalogs often list synonyms drawn from detailed nomenclature: Leucomycin A3, Ketamycin, Mykamycin, among others. Each variation ties back to the same critical function, though local preferences or regulations may make one name more familiar than others in different regions.
Handling antibiotics demands respect for science and safety. Workers in production facilities wear gloves and filtered masks to keep inhalation and skin contact to a minimum. Spills get handled fast, since repeated exposure can spark allergic responses. Waste management follows robust protocols—spent fermentation broth receives treatment to avoid environmental contamination or antibiotic resistance buildup. Regulatory approval hinges on documentation: purity logs, batch breakdowns, and contamination checks. Veterinary guidelines strictly control use to prevent overprescription and reduce the risk of residues winding up on supermarket shelves.
In the medical world, kitasamycin plays a somewhat niche role—respiratory tract infections, skin and soft tissue cases, and certain mycoplasma-driven ailments like whooping cough get the nod. In many countries, its use shifted out of the hospital and into the barn, where it became essential for holding down outbreaks in pigs, poultry, and calves. Respiratory and gastrointestinal diseases take a big toll on farm income, so quick, targeted antibiotic use keeps animals healthy and helps the food supply stay stable. It’s worth noting, though, that regulations now limit use in feed or water to keep resistance at bay and preserve the drug’s usefulness.
Researchers never slow down their work on macrolides, because bacteria keep cooking up new tricks. In the last few years, molecular biologists mapped key resistance genes in pathogens like Staphylococcus aureus and Mycoplasma—and found that small chemical shifts in kitasamycin’s structure can overcome certain enzymes. Structural biologists use X-ray diffraction and NMR to analyze exactly how kitasamycin gloms onto the ribosome. Universities and private firms chase tweaks that might give the drug a second life, whether that’s combining it with resistance blockers or threading it into new multi-drug therapies. Papers from labs in Japan, Europe, and the Americas read a bit like battle reports, showing where resistance surges and which modifications offer hope.
The safety record for kitasamycin looks good when stacked against many older antibiotics. Acute dosing in laboratory animals rarely causes outright toxicity, but chronic high doses bring out liver and kidney stress, as well as gut woes. In people, the most common side effects line up with what one expects from macrolides—nausea, diarrhea, and the rare risk of hearing changes. Regulators study kitasamycin residues in food animals with a microscope, setting maximum allowable levels and regular testing, since trace antibiotics in pork or eggs can trigger allergic responses in sensitive eaters. Toxicology teams keep the data moving, updating risk levels as analytical instruments gain sensitivity.
Antibiotic resistance throws challenges at scientists and policymakers. Kitasamycin now sees careful use, often as a fallback when first-line drugs falter or in carefully managed livestock disease outbreaks. New combinations with beta-lactams or efflux pump inhibitors show promise in the lab, and ongoing clinical trials may yet open new indications. Firm policies on stewardship matter more now than ever—avoidable overuse could see this toolkit close for good. Yet for the right case, kitasamycin keeps delivering value, and research into smart modifications and delivery methods means there’s more to come before its story closes. The landscape keeps moving as resistance patterns shift, but drugs with a grounded manufacturing base and adaptable chemistry like kitasamycin won’t vanish from the toolbox anytime soon.
Kitasamycin steps into the spotlight when doctors and veterinarians battle stubborn bacterial infections. This macrolide antibiotic, discovered decades ago, gained a reputation for tackling bacteria that shrug off common treatments. Unlike some broad-spectrum drugs, kitasamycin zeros in on a specific group of bacteria. This makes it an important choice, especially in places where patients or animals react poorly to other medicines.
In human medicine, kitasamycin often pops up in countries across Asia for respiratory tract infections. Doctors sometimes turn to it for tonsillitis, pharyngitis, and pneumonia, especially in cases tied to Streptococcus and Mycoplasma. Sometimes, it helps those who get side effects from other drugs like penicillin or erythromycin. Though not seen as much as in the past, it still fills a crucial niche in hospitals and clinics.
Kitasamycin plays a big role in livestock care. Farmers and veterinarians rely on it to keep chickens, pigs, and cattle healthy. It tackles diseases like chronic respiratory infections, enteric disorders, and mastitis in cattle. In many parts of the world, this antibiotic gets added to feed or water when animals fall sick. It’s a practical solution for keeping infections from ripping through whole herds or flocks.
But that kind of widespread use brings up tough questions. Over-the-counter access and regular use in healthy animals can build up resistant bacteria. These bacteria can pass from animals to humans — not just in farm communities, but on vegetables irrigated with untreated manure, or through meat that skips proper cooking. The risks tied to antimicrobial resistance aren’t just a topic for medical researchers; they have real, everyday consequences for families, food safety, and the entire chain of farming.
Bacteria change quickly when faced with antibiotics on a regular basis. Some strains shrug off drugs that used to wipe them out with ease. The World Health Organization singles out antimicrobial resistance as a top health concern. Studies show resistance trends aren’t just data points; it means fewer reliable ways to treat sick kids or manage outbreaks in barns. The more kitasamycin is used without careful oversight, the fewer options doctors and farmers will have down the road.
One way to hold on to kitasamycin’s value is to set clear rules about when it should be prescribed. Governments and industry groups draw up usage guidelines to keep these drugs out of healthy animals’ feed and limit doses only to confirmed infections. This calls for vet oversight and proper identification of what’s making the animal sick, instead of guessing or dosing whole flocks as a precaution.
On the farm, better cleanliness and smart animal husbandry make a huge difference. My experience working with local farmers has shown that small changes — like improving water systems, regular barn cleaning, and reducing animal crowding — cut down disease risk more than any single medication can. In hospitals, running simple swab tests to see which bacteria grew in a patient’s infection can steer the doctor to the right drug, rather than leaning on kitasamycin as an all-purpose fix.
If doctors, farmers, and patients all work together to use kitasamycin wisely, its power to heal can stick around longer. Using antibiotics thoughtfully isn’t just good science; it’s everyday common sense that matters for everyone’s future.
Kitasamycin, a macrolide antibiotic, often comes up as a solution when doctors must treat certain bacterial infections. Like many antibiotics, its job is to knock out the bacteria causing trouble, not viruses or fungi. Yet, any medicine that steps in to fight bacteria can also trigger some reactions in the body. Based on both personal experience with patients and medical literature, it’s clear that no two bodies respond in exactly the same way. Still, there are a handful of side effects that show up more often than others.
Stomach troubles rank as the most common reason people complain after starting kitasamycin. Nausea and mild cramps sometimes come first, but diarrhea deserves special attention. With some antibiotics, the drug doesn’t just attack the bacteria causing disease but may also mess with helpful bacteria in the gut. This change leaves the stomach feeling unsettled and can upset routines—including meals and sleep schedules. In my years observing families and talking with patients, nearly everyone using a strong antibiotic like kitasamycin has a story about a few days of stomach trouble.
Even more, some people taste a slight bitterness if the medicine comes as a liquid or dissolves in the mouth. This taste often lingers, reminding patients that medicine doesn’t always try to blend in with the senses.
After digestive changes, skin reactions hold the next spot on the usual list. Rashes, itching, and sometimes hives pop up in some patients. Whether young or old, that itch draws attention. Medical sources estimate around 5% of people get a skin reaction from macrolide antibiotics. Though most rashes fade fast, some rare people may slide into swelling of the face or difficulty breathing. This calls for a fast response—no one should wait and see with swelling around the mouth or throat.
Liver function sometimes changes after using kitasamycin. While unusual, some blood tests done at clinics pick up higher liver enzymes. This rarely becomes a crisis but should put the doctor on alert, especially in anyone with past liver problems. In the rarest cases, jaundice—yellowing of the skin or the whites of the eyes—may follow.
Hearing problems such as ringing or a sense that sounds are dampened pop up in medical literature for drugs in the same family, though these side effects are less common. People should mention any changes to their doctor quickly, since hearing loss linked to antibiotics can become permanent if unnoticed.
Doctors often adjust the dose based on weight, age, and kidney or liver function, cutting the risk of some side effects. Patients who drink lots of water, eat small, gentle meals, and keep an eye out for symptoms tend to move past the most common troubles without much lasting harm. Bringing up a family history of allergies or bad reactions to other antibiotics helps the doctor pick a safer option from the start.
Modern guidelines stress finishing the course prescribed, not stopping early because of side effects unless a doctor says otherwise. Pausing or swapping medicines should always follow a real conversation with a healthcare provider. Smart choices, open communication, and self-awareness keep most people safe while fighting infections.
Kitasamycin sits in the family of macrolide antibiotics, trusted for tackling bacterial infections, especially in areas like the respiratory tract, skin, and soft tissues. Doctors often pick this antibiotic for people who need a gentler option than penicillins. I’ve seen its use in both kids and adults who fight off stubborn throat infections or skin breakouts that just won’t heal with regular antibiotics. Kitasamycin gets to work by blocking bacteria from making essential proteins, so the germs can’t grow or spread further.
Pharmacies and hospitals carry Kitasamycin in several forms—tablets, oral suspensions, and injectables. Regular folks often stick with tablets or liquid since shots usually happen in a clinical setting. For adults, doctors tend to prescribe doses that simply match the weight of infection and patient. Kids usually take a suspension, since drinking medicine goes down easier than swallowing a pill, and the dose fits their unique size and needs. Relying on a precise measuring device, not a kitchen spoon, always brings a safer result. I’ve seen parents struggle with teaspoons at home and end up dosing either too little or too much. This simple switch makes all the difference.
Following the advice from your healthcare team can mean the difference between a quick recovery and lingering symptoms. People sometimes quit halfway down the bottle or skip pills when things start feeling better—this only helps the strongest bacteria stick around. Public health experts and infectious disease doctors all warn about this trend. Antibiotic resistance keeps doctors up at night. That’s why sticking with the full Kitasamycin schedule, and not missing doses, protects both the patient and the wider community. If there’s a next time, that infection won’t bounce back even tougher.
A lot of folks want to know if they should take Kitasamycin with or without food. Kitasamycin absorbs just fine on an empty stomach, but some stomachs handle it better with a meal. If nausea kicks in, eating a small snack before the dose can really help. Paying attention to the daily schedule matters, too—picking regular times for each dose keeps the amount of medicine in the body steady, giving bacteria little chance to regroup. Sticking reminders on the fridge or setting alarms turned out to be a huge help for busy families I’ve worked with.
No medicine comes without risk. Stomach upset, mild diarrhea, and even mild skin rashes pop up in some people. People allergic to macrolide antibiotics should steer clear. Liver issues also call for special attention, because the liver breaks down this medicine. Always tell the doctor if you take other prescribed drugs, since mixing antibiotics with blood thinners or some heart medicines can spark problems. Pharmacists can double-check for these issues, too, making them a key ally in safe care. Speaking up about all medicines—prescribed, herbal, or over-the-counter—keeps things straightforward and safe.
Getting Kitasamycin right isn’t just about swallowing pills. It takes teamwork between patients, doctors, and pharmacists. Clear instructions, dependable routines, and honest conversations about side effects or other medicines can turn a prescription into a true fix. With careful use, Kitasamycin stays a valuable player in the toolkit against tough infections, from busy households to overwhelmed clinics.
Kitasamycin pops up as an antibiotic choice in some parts of the world, especially across Asia. It belongs to the macrolide family, much like erythromycin and clarithromycin. Doctors turn to drugs in this group when fighting infections, especially in kids with allergies to penicillin. The big question many parents and expectant mothers raise is whether it offers the same safety margin as its better-known cousins or brings different risks to the table.
Experts don’t have a mountain of research on Kitasamycin use in children and pregnant women compared to older, more established antibiotics. Published studies tend to focus on lab results or animal studies. Human data gets harder to find. Some countries have used Kitasamycin for decades in pediatrics for respiratory infections and in obstetrics for cases where other choices run out. This track record suggests it can work but doesn’t mean it always belongs at the top of the list.
Macrolide antibiotics, in general, bring less risk for certain side effects compared to older drugs. They skip some of the severe allergic reactions seen with penicillins. Gastrointestinal upsets like nausea and diarrhea still occur in children who take Kitasamycin. Some children experience abdominal pain or rashes after a dose. Injectables cause soreness at the site. Experienced pediatricians say these reactions pass quickly, but supervision remains key. No child should take antibiotics without a prescription, since overuse leads straight to antibiotic resistance.
Safety during pregnancy always sparks intense debate. Most guidelines list erythromycin as the preferred macrolide because its risk profile got a thorough check by researchers over decades. For Kitasamycin, robust pregnancy studies don’t exist. Only animal studies show no birth defects at usual doses, but these results don’t always match real-life pregnancy. Women sometimes face infections that demand prompt treatment—waiting for perfect safety data proves impossible. In countries where Kitasamycin gets prescribed, doctors watch closely for allergic or digestive problems. They also monitor whether the infection actually responds, because ineffective antibiotics help no one.
Global agencies like the World Health Organization and American College of Obstetricians and Gynecologists place Kitasamycin outside their shortlists for routine use in pregnancy and childhood. They urge sticking with drugs that have endured more research scrutiny. National drug regulators in countries where Kitasamycin appears on hospital shelves allow its use if nothing else works. Before handing it out, doctors always try alternatives and check drug allergies and pregnancy status.
To make antibiotic use safer, governments and hospitals push for better reporting of side effects and more head-to-head studies comparing safety and results. The goal remains: keep babies, kids, and mothers as healthy as possible while fighting infections quickly and precisely. The advice never changes—never start antibiotics without a real need and always ask doctors about other options, especially during pregnancy.
Parents and pregnant women want peace of mind, so clear information matters. If a doctor suggests Kitasamycin, it comes from a place of weighing infection risk against drug safety and availability. Asking questions and reading up on guidance from official sources leads to better decisions. More research could fill in the blanks about rare side effects and long-term safety, but for now, doctors and families make the best choice with the evidence and experience available. Staying informed and cautious remains the best strategy in these high-stakes moments.
Kitasamycin belongs to the macrolide family of antibiotics, often used outside the United States. Some folks might see it prescribed for infections, especially when more regular antibiotics won't do. Though not as common as azithromycin or erythromycin in North America, Kitasamycin still pops up in prescriptions around the world. Safety doesn't come from simply trusting a medicine; it grows when people understand what it might do with other drugs taken at the same time.
Taking Kitasamycin with other drugs can create trouble. Macrolides like this one tend to slow down the body's ability to break down some medicines in the liver. For example, they can block an enzyme called CYP3A4. Drugs that depend on this enzyme—think statins for cholesterol, carbamazepine for seizures, or even some common antihistamines—may pile up in the body instead of getting cleared out. People on several medicines, especially older folks or those living with long-term health issues, face greater risk.
In years working alongside pharmacists, I've seen patients land with trips to the clinic from mixing the wrong antibiotics with everyday medicines. One regular visitor had muscle pain and got a prescription for Kitasamycin from abroad. Nobody realized he was also on simvastatin. Week later, muscle breakdown showed up—a potentially life-threatening outcome linked to the two drugs together. If the prescriber or pharmacist had probed further, that chain of events could have ended before it started.
Not only do the obvious drugs run into roadblocks. Blood thinners—like warfarin—can behave oddly with macrolides, sometimes leading to dangerous bleeding. Anti-seizure medicines might suddenly stop working well, or the heart can speed up and set off a rhythm problem when the medicine messes with calcium channel blockers. Even herbal products don't escape; for instance, St. John's Wort can reduce antibiotic levels, which lowers their bacteria-fighting power. Everyday over-the-counter antacids may also impact how these drugs are absorbed, yet few people think to mention them at the doctor’s office.
Language differences, lack of records, or rushed doctors contribute. Online pharmacies ship antibiotics around the world, making it easy for someone to end up with Kitasamycin without clear drug histories or pharmacist checks. Folks forget to mention vitamins, supplements, or medicines started by another doctor. Pressures on clinics mean less time to check every drug a person uses.
People using Kitasamycin should bring every medicine and supplement—prescription, non-prescription, and herbal—when seeing doctors or pharmacists. Insist they check for clashes. Pharmacists know how to spot these interactions and give advice on timing or substitutions. Electronic records and medicine lists on phones can help keep important details straight, reducing mistakes even if someone travels. Community outreach and plain-language guides also turn complicated science into advice everyone can use.
Slow down and ask. Take a moment at every doctor or pharmacy visit to update your list and point out any changes. If you’re traveling or seeing new healthcare providers, keep a card in your wallet listing all your medicines. Healthcare teams protect patients best when everyone feels comfortable sharing small details that could turn into big problems.
| Names | |
| Preferred IUPAC name | (3R,4S,5S,6R,7R,9R,11E,13R,14R)-4-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-14-ethyl-7,13,15-trimethyl-6-[(3,4,6-trideoxy-3-dimethylamino-β-D-xylo-hexopyranosyl)oxy]oxacyclopentadeca-11,16-dien-2-one |
| Other names |
Kitasamycinum Katasamycin Kytamycin Leucomycin Leucomycine |
| Pronunciation | /ˌkɪtəˈsæmɪsɪn/ |
| Identifiers | |
| CAS Number | 87-89-8 |
| 3D model (JSmol) | `3D model (JSmol)` string for **Kitasamycin**: ``` CC1C(C(C(O1)C2C(C(C(OC2OC3CC(C(C(O3)C)O)OC)CO)O)OC)OC(=O)C=C(C)C)C(=O)N(C)C ``` |
| Beilstein Reference | 1320803 |
| ChEBI | CHEBI:6104 |
| ChEMBL | CHEMBL176284 |
| ChemSpider | 16114 |
| DrugBank | DB06075 |
| ECHA InfoCard | 100.119.766 |
| EC Number | 132-68-3 |
| Gmelin Reference | 65006 |
| KEGG | D04558 |
| MeSH | D017265 |
| PubChem CID | 656927 |
| RTECS number | XN8220000 |
| UNII | Q99T8Y6M0V |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C35H59NO13 |
| Molar mass | 844.063 g/mol |
| Appearance | White or almost white crystalline powder |
| Odor | Odorless |
| Density | 1.16 g/cm³ |
| Solubility in water | Slightly soluble |
| log P | 3.14 |
| Acidity (pKa) | 7.74 |
| Basicity (pKb) | 8.6 |
| Magnetic susceptibility (χ) | -85.0×10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.59 |
| Dipole moment | 4.62 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 240.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of combustion (ΔcH⦵298) | -8759 kJ/mol |
| Pharmacology | |
| ATC code | J01FA93 |
| Hazards | |
| Main hazards | Harmful if swallowed, causes skin and eye irritation, may cause respiratory irritation |
| GHS labelling | GHS07, GHS08 |
| Pictograms | GHS05,GHS07 |
| Signal word | Warning |
| Hazard statements | H319: Causes serious eye irritation. |
| Precautionary statements | P264, P270, P273, P301+P312, P330, P501 |
| NFPA 704 (fire diamond) | Health: 1, Flammability: 1, Instability: 0, Special: - |
| Flash point | Flash point: 72.8°C |
| Autoignition temperature | Autoignition temperature: 400°C |
| Lethal dose or concentration | LD₅₀ (oral, rat): >4000 mg/kg |
| LD50 (median dose) | LD50 (median dose) of Kitasamycin: "6,000 mg/kg (oral, mouse) |
| NIOSH | SKJ000 |
| PEL (Permissible) | PEL (Permissible) of Kitasamycin: Not established |
| REL (Recommended) | 20–40 mg/kg per day in 2–4 divided doses |
| IDLH (Immediate danger) | Not Listed |
| Related compounds | |
| Related compounds |
Josamycin Midecamycin Spiramycin Tylosin |
